Sulzer Medica Ne-Osteo
This article was originally published in The Gray Sheet
Executive Summary
Bone morphogenic protein product development program is terminated Oct. 9. Sulzer says it "does not feel the program will yield the required commercial results." Regulatory obstacles had been encountered by two potential competitors in the bone growth factor area - Stryker and Wyeth-Ayerst (1"The Gray Sheet" July 9, 2001, p. 14). The company plans to close a related Denver facility, lay off about 60 workers and concentrate its continuing U.S. biologics R&D efforts in Austin. Thomas Zehnder, VP-business and technology development, will replace former Sulzer Biologics President Jerry Marlar, who has resigned. One-time restructuring costs of $7 mil. and annual savings of $8 mil. are anticipated. Sulzer booked a second-quarter loss of about $399 mil. due to the Inter-Op hip recall
You may also be interested in...
Centerpulse Biologics Unit To Be Split Up Under Evolving Reorganization Plan
Centerpulse's Biologics and Strategic Development Division activities will be integrated into the firm's remaining operating units under a reorganization plan that also includes dismissal of CEO Stephan Rietiker
Centerpulse Biologics Unit To Be Split Up Under Evolving Reorganization Plan
Centerpulse's Biologics and Strategic Development Division activities will be integrated into the firm's remaining operating units under a reorganization plan that also includes dismissal of CEO Stephan Rietiker
Rietiker Tightens Belt At Sulzer Medica By Cutting Staff, Consolidating
Sulzer IntraTherapeutics, a unit within Sulzer Medica's Cardiovascular Division, will cut 21% of its staff as part of a company-wide effort to cut costs and improve operating efficiency, the company announced Oct 23.